The investment seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the John Hancock Dimensional Healthcare Index. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities that compose the fund's benchmark index. The index is designed to comprise securities in the healthcare sector within the U.S. Universe whose market capitalizations are larger than that of the 1001st largest U.S. Company at the time of reconstitution. The fund is non-diversified.
Inception Date: 29/09/2015
Primary Benchmark: JH Dimensional Healthcare TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 1.23%
Management Expense Ratio: 0.50 %
|JNJ||Johnson & Johnson||6.19 %|
|UNH||UnitedHealth Group Incorporated (DE)||5.70 %|
|PFE||Pfizer Inc.||5.25 %|
|AMGN||Amgen Inc.||3.57 %|
|ABBV||AbbVie Inc.||3.15 %|
|MRK||Merck & Company Inc. (new)||3.01 %|
|GILD||Gilead Sciences Inc.||2.45 %|
|ESRX||Express Scripts Holding Company||2.42 %|
|MDT||Medtronic plc.||2.28 %|
|ANTM||Anthem Inc.||2.22 %|
|XLV||SPDR Select Sector Fund - Heal..||0.14 %||
|VHT||Vanguard Health Care||0.10 %||
|XBI||SPDR Series Trust S&P Biotech||0.35 %||
|IYH||iShares U.S. Healthcare||0.44 %||
|IXJ||iShares Global Healthcare||0.48 %||
|IHI||iShares U.S. Medical Devices||0.44 %||
|FBT||First Trust Amex Biotech Index..||0.56 %||
|FXH||First Trust Health Care AlphaD..||0.62 %||
|HQH||Tekla Healthcare Investors||0.00 %||
|FHLC||Fidelity MSCI Health Care Inde..||0.08 %||
|Market Performance vs.
|Market Performance vs. Exchange (NYSE Arca)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||7.84%||96%||A||82%||B-|
|Risk Adjusted Return||84.31%||64%||D||70%||C-|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company has under performed its peers on annual average total returns in the past 5 years.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.